Portfolio Alerts Watch List Cart

Healthcare

Refine Search


Product Compare (0)
J
Jagsonpal Pharmaceuticals Ltd
Score 68/100• Decent
Jagsonpal Pharmaceuticals Ltd shows potential but faces significant challenges in profitability and valuation metrics. Caution is advised for investors.
Company’s Health94/100
Valuation 20/100 · PB 5.6345
Technical Avoid
1M -5.857% 6M -13.858% 1Y -23.65%
Confidence100%
Low leverage (D/E)No promoter pledge
#91
View details ➜
J
J B Chemicals and Pharmaceuticals Ltd
Score 68/100• Decent
J B Chemicals and Pharmaceuticals Ltd shows decent potential with a stable growth outlook, but investors should be cautious of execution risks and valuation metrics.
Company’s Health95/100
Valuation 20/100 · PB 8.2037
Technical Avoid
1M -0.253% 6M 3.02% 1Y -2.322%
Confidence100%
Low leverage (D/E)No promoter pledge
#92
View details ➜
I
IPCA Laboratories Ltd
Score 68/100• Decent
IPCA Laboratories Ltd shows potential for growth, but investors should be cautious due to profitability inconsistencies and valuation concerns.
Company’s Health80/100
Valuation 40/100 · PB 4.4336
Technical Avoid
1M 11.915% 6M 5.994% 1Y -6.062%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#93
View details ➜
I
Indoco Remedies Ltd
Score 68/100• Decent
Indoco Remedies Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
Company’s Health56/100
Valuation 60/100 · PB 2.195
Technical Avoid
1M -10.586% 6M -13.499% 1Y -27.629%
Confidence100%
No promoter pledgeReasonable PB valuation
Weak ROEThin margins
#94
View details ➜
H
Hindustan Bio Sciences Ltd
Score 68/100• Decent
Hindustan Bio Sciences Ltd shows potential but faces significant challenges in growth and profitability metrics. Caution is advised for investors.
Company’s Health33/100
Valuation 20/100 · PB 6.9364
Technical Avoid
1M -18.245% 6M -34.586% 1Y -41.103%
Confidence100%
No promoter pledgeHealthy profit margins
Weak ROEHigh debt/equity
#95
View details ➜
G
Gufic Biosciences Ltd
Score 68/100• Decent
Gufic Biosciences Ltd shows potential for growth in a promising sector, but faces challenges in profitability and valuation metrics. Investors should proceed with caution.
Company’s Health90/100
Valuation 20/100 · PB 5.8094
Technical Avoid
1M 8.501% 6M -6.599% 1Y -20.009%
Confidence100%
No promoter pledge
#96
View details ➜
F
Fortis Healthcare Ltd
Score 68/100• Decent
Fortis Healthcare Ltd shows potential in a growing sector but faces challenges in execution and competition. Caution is advised.
Company’s Health67/100
Valuation 20/100 · PB 7.1965
Technical Avoid
1M -14.543% 6M 15.007% 1Y 21.177%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#97
View details ➜
D
Dr Lalchandani Labs Ltd
Score 68/100• Decent
Dr Lalchandani Labs Ltd shows potential in a growing sector, but faces challenges in growth consistency and valuation metrics. Caution is advised.
Company’s Health46/100
Valuation 100/100 · PB 0.7834
Technical Avoid
1M -6.4% 6M 15.026% 1Y 10.64%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#98
View details ➜
D
Dr Agarwal's Eye Hospital Ltd
Score 68/100• Decent
Dr Agarwal's Eye Hospital Ltd shows potential for growth, but faces challenges in profitability and valuation metrics compared to peers.
Company’s Health68/100
Valuation 20/100 · PB 12.7754
Technical Avoid
1M 5.827% 6M 23.695% 1Y 1.594%
Confidence100%
Healthy profit marginsDecent revenue growth
High debt/equityPromoter pledge present
#99
View details ➜
D
DocMode Health Technologies Ltd
Score 68/100• Risky
DocMode Health Technologies Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health40/100
Valuation 60/100 · PB 2.5876
Technical Avoid
1M -35.546% 6M 10.709% 1Y -26.901%
Confidence100%
Reasonable PB valuation
Weak ROEPromoter pledge present
#100
View details ➜
C
Concord Biotech Ltd
Score 68/100• Decent
Concord Biotech Ltd shows potential for growth but faces challenges in valuation and execution risks.
Company’s Health94/100
Valuation 20/100 · PB 7.9054
Technical Avoid
1M -6.42% 6M -33.621% 1Y -36.064%
Confidence100%
Low leverage (D/E)No promoter pledge
#101
View details ➜
B
Bharat Parenterals Ltd
Score 68/100• Decent
Bharat Parenterals Ltd shows potential for growth, but faces challenges in profitability and market competition.
Company’s Health64/100
Valuation 60/100 · PB 2.2949
Technical Avoid
1M -3.313% 6M -9.144% 1Y -35.65%
Confidence100%
No promoter pledgeDecent revenue growth
Weak ROEThin margins
#102
View details ➜
A
Asarfi Hospital Ltd
Score 68/100• Decent
Asarfi Hospital Ltd shows potential in a growing sector but faces challenges in profitability and valuation. Caution is advised.
Company’s Health89/100
Valuation 40/100 · PB 4.6648
Technical Momentum
1M 16.106% 6M 41.959% 1Y 76.341%
Confidence100%
No promoter pledgeDecent revenue growth
#103
View details ➜
A
Aspira Pathlab & Diagnostics Ltd
Score 68/100• Decent
Aspira Pathlab & Diagnostics Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Caution is advised.
Company’s Health77/100
Valuation 20/100 · PB 5.2866
Technical Avoid
1M 10.774% 6M 11.117% 1Y -0.16%
Confidence100%
Low leverage (D/E)No promoter pledge
#104
View details ➜
A
Aristo Bio-Tech and Lifescience Ltd
Score 68/100• Decent
The company operates in a promising sector but faces challenges in growth consistency and profitability metrics.
Company’s Health72/100
Valuation 60/100 · PB 2.0872
Technical Avoid
1M -10.235% 6M -7.702% 1Y -24.828%
Confidence100%
No promoter pledgeDecent revenue growth
Weak ROEThin margins
#105
View details ➜
Showing 91 to 105 of 301 (21 Pages)